Donald Trump said the US would “take over” the Gaza Strip and that its 2.2mn inhabitants should be permanently resettled in ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

A broad measure of Asian equities slipped, pressured by sell-offs in Hong Kong and mainland China. Futures for the S&P 500 ...

US imports surged to a record high in December, official figures showed today as Donald Trump’s threat of tariffs triggered a ...

The three sites in Anagni, Italy, Brussels in Belgium ... of its rivals in the diabetes and obesity category, notably Eli Lilly, which has also faced supply issues with diabetes therapy Mounjaro ...

Torie Neubauer led East with 21 points and Lilly Meulemans added 19 as the Patriots ... most likely to make it to the WIAA state tournament BRUSSELS - The Lions led by 12 points at halftime ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.